New at the ISN Academy – ISN-ASON Case Series on Onconephrology: Watch the First Case on Immune Checkpoint Inhibitorsjbrown
The ISN and the American Association of Onconephrology (ASON) are collaborating on a series of case presentations to promote research, clinical activities, and education in onconephrology.
Immune checkpoint inhibitors (ICPI) have transformed the landscape of cancer therapy. They are currently the cornerstone of treatment for several cancers, even in advanced stages.
However, widespread T-cell activation arising from the treatment can lead to mild to life-threatening autoimmune side effects in any organ system.
In this case, presented by Pooja Amarapurkar (USA), find out:
- How these medications work
- How they cause immune-related adverse events
- How to manage patients with ICPI-related AKI